Key result
The application of whole-exome sequencing and human genetics can streamline the discovery of causal genetic mutations, such as PCSK9 loss-of-function mutations found in ~2.5% of African Americans.
Human genetics, particularly whole-exome sequencing, can identify causal genetic mutations like PCSK9, ANGPTL3, and APOC3 to discover new therapeutic targets for lipid management and CHD prevention.
Answers are grounded in this paper and cite their sources.
Supports genetic target discovery for lipids; leaves open translation to CHD prevention without prospective validation.
Genetic variation arises through multiple different alleles that vary in frequency and severity of effect. Mutations that give rise to Mendelian disorders, such as the LDL receptor (LDLR) mutations that result in familial hypercholesterolaemia, are efficiently winnowed from the population by purifying selection and are almost inevitably rare. Conversely, alleles that are common in the population (such that homozygotes for the minor allele are present even in modest sample sizes) typically have very modest phenotypic effects. Mutations in the gene for proprotein convertase subtilisin/kexin type 9 (PCSK9) represent an unusual but informative exception in that they are relatively common but have large effects on phenotype. Loss-of-function mutations in PCSK9 occur in ~2.5% of African Americans and are associated with large reductions in coronary heart disease (CHD) risk. The development of agents to inhibit PCSK9 demonstrates the utility of translating genetics into clinical therapeutics. Attempts to identify genes responsible for hypercholesterolaemia have used traditional linkage analysis, which requires samples collected from multiple families with defects in the same gene, or genome-wide association, which requires thousands of samples from the population. More recently, whole-exome sequencing studies have revealed loss-of-function mutations in ANGPTL3 associated with pan-hypolipidemia, and in APOC3 that confer protection against CHD. The application of whole-exome sequencing to large populations or to carefully selected patients can streamline the discovery of causal genetic mutations.
No takes yet. Share an insight, caveat, or question.
Jonathan C. Cohen (2016) conducted a review in Hypercholesterolaemia and coronary heart disease. Human genetics and whole-exome sequencing was evaluated. The application of whole-exome sequencing and human genetics can streamline the discovery of causal genetic mutations, such as PCSK9 loss-of-function mutations found in ~2.5% of African Americans.
Synapse has enriched 10 related papers. Consider them for comparative context: